By publishing our learnings in medical journals and media outlets, we promote the availability of promising treatments and educate the public about options for dealing with a complex cancer diagnosis.
Advances in technology have yielded promising results for patients and expanded our knowledge of TCRs. We can now identify TCRs that correspond to cancer-specific antigens. Allowing us to gain a deeper understanding of the anti-cancer immune response and identify potential targets for individualized cancer treatments. This breakthrough empowers the next generation of personalized T-cell-based therapies, enabling us to leverage these sequences to develop treatments. Through immune monitoring, we can track and quantify the immune response against specific targets, providing insights into the effectiveness of immunotherapies and other treatments.
Our team has expertise focused on many aspects of personalized medicine and experience helping patients with many forms of cancer. We build partnerships with providers, companies, and foundations devoted to help patients.
In this study, personalized medicine changed the course of a patient with advanced pancreatic cancer. Tumor sequencing helped identify a unique set of mutations in the tumor, which were used to develop a personalized cancer vaccine. Following treatment with vaccine, the patient went into remission and testing suggests that the vaccine stimulated an immune response against the cancer.
Prophylactic use of personalized vaccine therapy helped to prevent recurrence in female breast cancer patients who were in remission. The patient’s tumor mutations were analyzed for vaccine development. The vaccines were designed to stimulate T-cell responses against the patients' individual tumor-specific antigens. Immune monitoring was used to detect the vaccine-induced T-cell responses. All the patients had continuous T-cell responses and remained tumor-free for several months after treatment.
Patients with recurrent bladder cancer have a poor prognosis. This study demonstrates the promise of vaccine treatment and immunotherapy in a patient with high-risk metastatic bladder cancer. Whole Exome Sequencing (WES) was performed to analyze tumor tissue and identify tumor-specific neoantigens. Following vaccine treatment, Immune monitoring was conducted using plasma Liquid Biopsy (pLB) to measure known tumor mutations in plasma circulating tumor DNA (ctDNA). This approach for tracking can impact all decisions around treatment.
We aim to collaborate with patients and foundations to advance our understanding of T-cell receptors and their potential to unlock novel treatment options. T-cell receptors (TCRs) are proteins on the surface of T cells that recognize and bind to specific antigens, triggering an immune response against cancer cells and other harmful threats. TCR Sequencing is a technique used to identify and analyze the genetic sequences of TCRs. This data can provide insights into T cell clones and the dynamics of immune responses in cancer.
Advances in technology have yielded promising results for patients and expanded our knowledge of TCRs. We can now identify TCRs that correspond to cancer-specific antigens. Allowing us to gain a deeper understanding of the anti-cancer immune response and identify potential targets for individualized cancer treatments. This breakthrough empowers the next generation of personalized T-cell-based therapies, enabling us to leverage these sequences to develop treatments. Through immune monitoring, we can track and quantify the immune response against specific targets, providing insights into the effectiveness of immunotherapies and other treatments.
If you would like additional information or looking to support, please contact us!